Pfizer (PFE) Q3 FY25 earnings call

Pfizer delivered solid Q3 FY25 results, driven by strong performance in its non-COVID portfolio and disciplined cost management, leading to an upward revision of full-year adjusted EPS guidance. The company is actively pursuing strategic M&A and licensing deals, such as the proposed Metsera acquisition and 3SBio licensing, to enhance its long-term pipeline and growth trajectory, despite near-term dilutive impacts and ongoing legal challenges.